Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20036563 | 0.88 | HPGD (0.37) | MEN1KMT2AHPGDRXRARXRB | |
| SCHEMBL15213085 | 0.85 | MEN1 (0.41) | MEN1KMT2AHPGDHSP90AA1HSP90AB1 | |
| SCHEMBL15201390 | 0.83 | FGFR1 (0.54) | MEN1KMT2AHPGDALDH1A1NPC1 | |
| SCHEMBL15213052 | 0.83 | MAOB (0.44) | MEN1KMT2AHPGDHSP90AA1HSP90AB1 | |
| SCHEMBL15213061 | 0.83 | GRM5 (0.44) | MEN1KMT2AHPGDHSP90AA1HSP90AB1 | |
| SCHEMBL15213091 | 0.83 | MAOB (0.44) | MEN1KMT2AHPGDHSP90AA1HSP90AB1 | |
| SCHEMBL16393837 | 0.83 | MAOB (0.44) | MEN1KMT2AHPGDHSP90AA1HSP90AB1 | |
| SCHEMBL2069436 | 0.81 | MAPT (0.54) | MEN1KMT2AHPGDALDH1A1NPC1 | |
| SCHEMBL15213131 | 0.79 | HPGD (0.46) | HPGDHSP90AA1HSP90AB1RXRARXRB | |
| SCHEMBL15213056 | 0.78 | HPGD (0.44) | MEN1KMT2AHPGDHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | KINETA VIRAL HEMORRHAGIC FEVER, LLC (US) | 2018-06-19 | — | — | US | claimed |
| CN-110698408-B | Antiviral drug for treatment of arenavirus infection | 奇尼塔病毒性出血热有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-110776453-A | Antiviral drug for treatment of arenavirus infection | 奇尼塔四有限责任公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-110698408-A | Antiviral drug for treatment of arenavirus infection | 奇尼塔四有限责任公司 | 2020-01-17 | — | — | CN | disclosed |
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | KINETA VIRAL HEMORRHAGIC FEVER, LLC (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | KINETA VIRAL HEMORRHAGIC FEVER, LLC (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2814486-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | KINETA FOUR LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2814486-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | KINETA FOUR LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Kineta Four, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Kineta Four, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Kineta Four, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9498470-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498470-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498470-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2015-01-22 | — | — | US | disclosed |
| WO-2013123215-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | EIF2AK2, ZC3HAV1, SARS1 | MEN1 4825/4885KMT2A 4695/4885HPGD 1798/4885 |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | MEN1 4825/4885KMT2A 4695/4885HPGD 1798/4885 |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | MEN1 4825/4885KMT2A 4695/4885HPGD 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.